구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant Immunomodulatory (IM, Adjuvant Immunomodulatory, Adjuvant Immunomodulatory (IM) Therapy) Ultragenyx Pharmaceutical Inc·Mucopolysaccharidosis IIIA 132 trials·t½ 47 h |
|---|---|
Overview Program | Adjuvant Immunomodulatory (IM) Therapy |
Overview Company | Ultragenyx Pharmaceutical Inc |
Overview Modality | ANTIBODY |
Overview Target | Mucopolysaccharidosis IIIA |
Overview Indication | Mucopolysaccharidosis IIIA; MPS IIIA |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | bispecific antibodies and pairwise interactions in antibody-dependent cell cytotoxicity events |
MoA Biomarker | biomarker levels were compared between groups |
PK/PD Half-life | 47 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | TIGIT-associated immune cell exhaustion in pediatric B-cell acute lymphoblastic leukemia: An integrated clinical and transcriptomic analysis.. Immune checkpoint dysregulation contributes to cytotoxic lymphocyte exhaustion in hematologic malignancies. TIGIT, an inhibitory immune receptor expressed on activated T and natural killer (NK) cells, is a key regulator of immune exhaustion. However, its tr… |
Clinical Safety signal | TIGIT-associated immune cell exhaustion in pediatric B-cell acute lymphoblastic leukemia: An integrated clinical and transcriptomic analysis.. Immune checkpoint dysregulation contributes to cytotoxic lymphocyte exhaustion in hematologic malignancies. TIGIT, an inhibitory immune receptor expressed on activated T and natural killer (NK) cells, is a key regulator of immune exhaustion. However, its tr… |
Clinical Selected reported efficacy | 9.4% |
Clinical Result source | ClinicalTrials.gov NCT02616185 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02616185 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Adjuvant Immunomodulatory (IM, Adjuvant Immunomodulatory, Adjuvant Immunomodulatory (IM) Therapy) Ultragenyx Pharmaceutical Inc·Mucopolysaccharidosis IIIA 132 trials·t½ 47 h |
|---|---|
Overview Program | Adjuvant Immunomodulatory (IM) Therapy |
Overview Company | Ultragenyx Pharmaceutical Inc |
Overview Modality | ANTIBODY |
Overview Target | Mucopolysaccharidosis IIIA |
Overview Indication | Mucopolysaccharidosis IIIA; MPS IIIA |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | bispecific antibodies and pairwise interactions in antibody-dependent cell cytotoxicity events |
MoA Biomarker | biomarker levels were compared between groups |
PK/PD Half-life | 47 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | TIGIT-associated immune cell exhaustion in pediatric B-cell acute lymphoblastic leukemia: An integrated clinical and transcriptomic analysis.. Immune checkpoint dysregulation contributes to cytotoxic lymphocyte exhaustion in hematologic malignancies. TIGIT, an inhibitory immune receptor expressed on activated T and natural killer (NK) cells, is a key regulator of immune exhaustion. However, its tr… |
Clinical Safety signal | TIGIT-associated immune cell exhaustion in pediatric B-cell acute lymphoblastic leukemia: An integrated clinical and transcriptomic analysis.. Immune checkpoint dysregulation contributes to cytotoxic lymphocyte exhaustion in hematologic malignancies. TIGIT, an inhibitory immune receptor expressed on activated T and natural killer (NK) cells, is a key regulator of immune exhaustion. However, its tr… |
Clinical Selected reported efficacy | 9.4% |
Clinical Result source | ClinicalTrials.gov NCT02616185 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02616185 |
추천 비교
추천 비교